BeOne Medicines (ONC) said Thursday that the phase 1 study of sonrotoclax plus BRUKINSA elicited a 96% overall response rate in relapsed/refractory chronic lymphocytic leukemia patients and a 79% overall response rate in relapsed/refractory mantle cell lymphoma patients.
BGB-16673 also showed "strong early results" in hard-to-treat populations, and the data support future regulatory filings and the progression of sonrotoclax and BGB-16673 into phase 3 studies, the company said.
The company's shares were up nearly 5% in recent Thursday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。